Your session is about to expire
← Back to Search
Peptide Vaccine for Carcinoid Tumor
Study Summary
This trial is testing a vaccine made of small pieces of protein to see if it can help the immune system to kill neuroendocrine tumor cells.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My neuroendocrine tumor tissue has tested positive for survivin.I am on full-dose anticoagulants and meet specific criteria.I am currently taking somatostatin analogues and can continue them during the study.I have not had cancer in the last 3 years, except for treated skin cancer or carcinoma-in-situ.I have HIV/AIDS or another serious illness.I do not have any conditions that cause frequent bleeding.I am taking more than 2 mg of dexamethasone or its equivalent daily.I haven't had immunotherapy for any cancer in the last 3 months.My cancer is a neuroendocrine tumor from the gut, pancreas, or lung.My cancer has worsened in the last 6 months, confirmed by scans.I had local therapy over 6 weeks ago and my treated cancer has grown since then.I can take care of myself with little help.I have a known autoimmune disorder.I do not have serious heart rhythm problems.
- Group 1: Treatment (SVN53-67/M57-KLH peptide vaccine, octreotide)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what ailments is SVN53-67/M57-KLH Peptide Vaccine commonly prescribed?
"SVN53-67/M57-KLH Peptide Vaccine is regularly employed as an intervention for hemopoietic stem cell transplant. Additionally, it can be used to combat side effects such as flushing, radiation syndrome and neutropenia among others."
What additional research has been conducted on SVN53-67/M57-KLH Peptide Vaccine?
"Presently, 10 trials of SVN53-67/M57-KLH Peptide Vaccine are in the Phase 3 stage. Of these 58 studies focused on this vaccine, many are held at Trabzon and Florida locations; yet there exist 2,679 sites conducting research into this particular peptide immunogen."
What is the recruitment quota for this medical experiment?
"Affirmative. As per the clinicaltrials.gov listing, this medical research is actively accepting patients since its posting on June 17th 2019 and latest update on August 10th 2022. A total of 14 participants are needed at a single location to complete the study requirements."
Are there opportunities for individuals to partake in this trial?
"This investigation is presently recruiting participants as indicated on clinicaltrials.gov; its inception was June 17th 2019 and it has been recently updated August 10th 2022."
Has the SVN53-67/M57-KLH Peptide Vaccine acquired FDA authorization?
"Our team at Power has classified SVN53-67/M57-KLH Peptide Vaccine as a safety level 1 due to being in the first clinical trial phase, where limited evidence of efficacy and security exists."
Share this study with friends
Copy Link
Messenger